Published in J Thromb Haemost on March 01, 2008
Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica (2011) 0.99
von Willebrand disease: clinical and laboratory lessons learned from the large von Willebrand disease studies. Am J Hematol (2012) 0.97
Perils, problems, and progress in laboratory diagnosis of von Willebrand disease. Semin Thromb Hemost (2013) 0.93
The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology. Br J Haematol (2014) 0.93
VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. Blood (2013) 0.93
Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort. Haematologica (2010) 0.83
Force-sensitive autoinhibition of the von Willebrand factor is mediated by interdomain interactions. Biophys J (2015) 0.82
Identification and characterisation of mutations associated with von Willebrand disease in a Turkish patient cohort. Thromb Haemost (2013) 0.81
Autosomal dominant C1149R von Willebrand disease: phenotypic findings and their implications. Haematologica (2009) 0.81
Shear-Induced Unfolding and Enzymatic Cleavage of Full-Length VWF Multimers. Biophys J (2016) 0.81
Pregnancy and delivery in women with von Willebrand's disease and different von Willebrand factor mutations. Haematologica (2009) 0.80
Exponential size distribution of von Willebrand factor. Biophys J (2013) 0.80
von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels. J Thromb Haemost (2010) 0.79
Biogenesis of Weibel-Palade bodies in von Willebrand's disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation. Haematologica (2011) 0.78
Identification and functional analysis of a novel von Willebrand factor mutation in a family with type 2A von Willebrand disease. PLoS One (2012) 0.76
Diagnostic approach to von Willebrand disease. Blood (2015) 0.76
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): a rebuttal. J Thromb Haemost (2008) 0.76
Mutation G1629E Increases von Willebrand Factor Cleavage via a Cooperative Destabilization Mechanism. Biophys J (2017) 0.75
Translational medicine advances in von Willebrand disease. J Thromb Haemost (2013) 0.75
Identification and characterization of the elusive mutation causing the historical von Willebrand Disease type IIC Miami. J Thromb Haemost (2016) 0.75
Rapid discrimination of the phenotypic variants of von Willebrand disease. Blood (2016) 0.75
Use of a rapid assay of subforms of creatine kinase-MB to diagnose or rule out acute myocardial infarction. N Engl J Med (1994) 7.17
What is the optimum interval between mammographic screening examinations? An analysis based on the latest results of the Swedish two-county breast cancer screening trial. Br J Cancer (1987) 6.20
Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med (1995) 5.85
Multiple essential functions of neuregulin in development. Nature (1995) 5.66
Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA (2005) 5.60
Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA (1998) 4.65
Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc Natl Acad Sci U S A (1985) 4.60
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med (1995) 4.32
High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA (1992) 4.31
The relation between survival and age at diagnosis in breast cancer. N Engl J Med (1986) 4.21
Adverse reactions to nitrofurantoin. Analysis of 921 reports. Am J Med (1980) 4.03
Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. J Cell Biol (2001) 3.84
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol (2007) 3.81
Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA (1997) 3.80
Gene deletions correlate with the development of alloantibodies in von Willebrand disease. J Clin Invest (1987) 3.73
Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation (2001) 3.33
Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol (1993) 3.32
Evolution of the primate lentiviruses: evidence from vpx and vpr. EMBO J (1992) 3.25
Epidemiological investigation of the prevalence of von Willebrand's disease. Blood (1987) 3.24
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost (2001) 3.13
Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996). J Clin Microbiol (1998) 3.10
Direct PCR from whole blood, without DNA extraction. Nucleic Acids Res (1990) 3.00
Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity (1996) 2.96
Ultrafast bond softening in bismuth: mapping a solid's interatomic potential with X-rays. Science (2007) 2.84
Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial. Uppsala-Orebro Breast Cancer Study Group. J Natl Cancer Inst (1994) 2.81
Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest (1992) 2.80
Congenital absence of the inferior vena cava: a rare risk factor for idiopathic deep-vein thrombosis. Lancet (2001) 2.78
Trends in prostate cancer survival in Sweden, 1960 through 1988: evidence of increasing diagnosis of nonlethal tumors. J Natl Cancer Inst (1996) 2.71
10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol (1999) 2.64
The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst (1996) 2.57
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost (2006) 2.56
Susceptibility locus for Alzheimer's disease on chromosome 10. Science (2000) 2.49
An encyclopedia of mouse genes. Nat Genet (1999) 2.48
Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol (1997) 2.46
The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost (2005) 2.45
Mutations in GLUT2, the gene for the liver-type glucose transporter, in patients with Fanconi-Bickel syndrome. Nat Genet (1997) 2.40
CYP98A3 from Arabidopsis thaliana is a 3'-hydroxylase of phenolic esters, a missing link in the phenylpropanoid pathway. J Biol Chem (2001) 2.32
Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost (1992) 2.31
The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology (1997) 2.29
Common-sense models of illness: the example of hypertension. Health Psychol (1985) 2.26
No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol (1998) 2.18
Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation (2004) 2.12
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol (2000) 2.09
Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol (1998) 2.09
Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation (1999) 2.09
Five-node biopsy of the axilla: an alternative to axillary dissection of levels I-II in operable breast cancer. Eur J Surg Oncol (2002) 2.09
Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast--results from the Swedish randomised trial. Eur J Cancer (2006) 2.09
[Preventive treatment of nonrheumatic atrial fibrillation: from the efficacy of clinical trials to the effectiveness of clinical practice]. Aten Primaria (1997) 2.04
Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood (1990) 2.04
Significant reduction in advanced breast cancer. Results of the first seven years of mammography screening in Kopparberg, Sweden. Diagn Imaging Clin Med (1985) 2.02
Expression studies on a novel type 2B variant of the von Willebrand factor gene (R1308L) characterized by defective collagen binding. J Thromb Haemost (2005) 2.02
A mammalian homologue of Drosophila heterochromatin protein 1 (HP1) is a component of constitutive heterochromatin. Cytogenet Cell Genet (1994) 2.01
Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer (1999) 1.99
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia (2013) 1.97
[Problems of interpretation in vascular surgery]. Lakartidningen (1993) 1.94
Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations. Br J Anaesth (2008) 1.93
Epidemiology and pathophysiology of cancer-associated thrombosis. Br J Cancer (2010) 1.93
Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. Ann Intern Med (1998) 1.91
Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland. J Cell Biol (1995) 1.91
Validated questionnaire for the identification of previous personal or familial venous thromboembolism. Am J Epidemiol (1996) 1.90
Fruit, vegetables, dietary fiber, and risk of colorectal cancer. J Natl Cancer Inst (2001) 1.90
Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood (1996) 1.89
A transcriptional insulator at the imprinted H19/Igf2 locus. Genes Dev (2000) 1.88
Increased metastatic potential of tumor cells in von Willebrand factor-deficient mice. J Thromb Haemost (2005) 1.88
Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens (2004) 1.86
A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant (2006) 1.84
European principles of haemophilia care. Haemophilia (2008) 1.84
Evidence that three adhesive proteins interact with a common recognition site on activated platelets. J Biol Chem (1984) 1.83